With a goal to collaborate on a variety of marketing efforts within the medical aesthetics industry, Revision Skincare® and RVL Pharmaceuticals, Inc. the owner of UPNEEQ®, are partnering to address what they see as significant unmet consumer needs.

Revisions says that, with shared values and visions for business growth and an expanding footprint, the collaboration aligns two game-changing brands to offer more accessible solutions to aesthetic patients and providers nationwide.

For more than two decades, Revision Skincare has been at the forefront of physician-dispensed brands. RVL Pharmaceuticals offers appropriate patients a nonsurgical solution for acquired ptosis and provides results in as little as 5 minutes with UPNEEQ, the first and only FDA-approved prescription eye drop for the treatment of acquired ptosis in adults.

"We know that RVL Pharmaceuticals has a lot of choices when it comes to commercial partnerships. We are excited to join this mission with RVL to offer breakthrough patient solutions," says Maria Carell, CEO, and President, Revision Skincare®.

Through the partnership, Revision Skincare® and RVL Pharmaceuticals will bring broader access to products like D·E·J Eye Cream®, Revox™ Line Relaxer, and UPNEEQ®. 

"We are thrilled to partner with Revision Skincare®! Their strong history of innovation and passion for skin health aligns with our core directive around ocular medical aesthetics," says Brian Markison, CEO, RVL Pharmaceuticals.